Dowling & Yahnke LLC Lowers Position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Dowling & Yahnke LLC reduced its stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 0.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 87,062 shares of the financial services provider’s stock after selling 745 shares during the quarter. Dowling & Yahnke LLC owned approximately 0.13% of iShares Nasdaq Biotechnology ETF worth $9,498,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. CX Institutional acquired a new position in shares of iShares Nasdaq Biotechnology ETF in the 1st quarter valued at $1,247,000. Clarus Wealth Advisors raised its stake in shares of iShares Nasdaq Biotechnology ETF by 2,076.7% in the 1st quarter. Clarus Wealth Advisors now owns 5,224 shares of the financial services provider’s stock valued at $584,000 after buying an additional 4,984 shares in the last quarter. Intl Fcstone Inc. acquired a new position in shares of iShares Nasdaq Biotechnology ETF in the 1st quarter valued at $201,000. XR Securities LLC acquired a new position in shares of iShares Nasdaq Biotechnology ETF in the 1st quarter valued at $1,116,000. Finally, F&V Capital Management LLC raised its stake in shares of iShares Nasdaq Biotechnology ETF by 17.7% in the 1st quarter. F&V Capital Management LLC now owns 6,583 shares of the financial services provider’s stock valued at $736,000 after buying an additional 990 shares in the last quarter. 72.66% of the stock is owned by institutional investors and hedge funds.

Shares of IBB stock opened at $106.38 on Friday. iShares Nasdaq Biotechnology ETF has a 52-week low of $89.01 and a 52-week high of $122.97. The firm has a fifty day simple moving average of $106.82.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Further Reading: What is a Fiduciary?

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.